Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312168 | 0.94 | KLKB1 (0.38) | ROCK1GRM4ROCK2KCNH2OPRM1 | |
| SCHEMBL3313654 | 0.90 | ROCK1 (0.39) | ROCK1GRM4KCNH2OPRM1MAPK7 | |
| SCHEMBL3312549 | 0.85 | ROCK1 (0.40) | ROCK1ROCK2KCNH2OPRM1KLKB1 | |
| SCHEMBL3315584 | 0.84 | OPRL1 (0.45) | ROCK1OPRM1MAPK7KLKB1KLK1 | |
| SCHEMBL3314206 | 0.84 | MAPK7 (0.35) | ROCK1GRM4ROCK2KCNH2OPRM1 | |
| SCHEMBL3320107 | 0.81 | ROCK1 (0.34) | ROCK1GRM4ROCK2KCNH2MAPK7 | |
| SCHEMBL3313658 | 0.80 | SIGMAR1 (0.34) | ROCK1GRM4ROCK2KCNH2MAPK7 | |
| SCHEMBL3317291 | 0.80 | ROCK1 (0.51) | ROCK1ROCK2KCNH2KLKB1KLK1 | |
| SCHEMBL3316205 | 0.78 | KDM4E (0.37) | ROCK1GRM4ROCK2KCNH2OPRM1 | |
| SCHEMBL3312181 | 0.78 | ROCK1 (0.41) | ROCK1GRM4ROCK2KCNH2MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | ROCK1 5/4885GRM4 3037/4885ROCK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.